Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

NOVO NORDISK A/S (NOVO.B)

231
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Copenhagen Stock Exchange
03/20/2015 03/23/2015 03/24/2015 03/25/2015 03/26/2015 Date
343.3 339.1 345.1 340.7 335 Last
3073480 2366533 2799579 2314316 3313776 Volume
+0.41% -1.22% +1.77% -1.27% -1.67% Change
Financials ( DKK)
Sales 2015 106 126 M
EBIT 2015 44 012 M
Net income 2015 30 703 M
Finance 2015 13 679 M
Yield 2015 1,65%
Sales 2016 115 306 M
EBIT 2016 48 178 M
Net income 2016 37 377 M
Finance 2016 16 161 M
Yield 2016 2,01%
PER 2015 28,73
PER 2016 23,25
EV / Sales 2015 6,65x
EV / Sales 2016 6,10x
Capitalization 719 751 M
More Financials
Company
Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products.It operates through the Diabetes Care and Biopharmaceuticals segments.The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of... 
Sector
Pharmaceuticals
Calendar
03/25 | 03:00amSpecial Situation
More about the company
Surperformance© ratings of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK A/S
12:30p NOVO NORDISK A/S : Novo Nordisk has decided to resubmit the New Drug Application..
12:25p NOVO NORDISK A/S : A/S : has decided to resubmit the New Drug Applications of Tr..
11:02a Zosano Pharma Reports 2014 Financial Results
03/25 NOVO NORDISK A/S : Novo Nordisk completes phase 3a trials comparing faster-actin..
03/25 NOVO NORDISK A/S : A/S: completes phase 3a trials comparing faster-acting insuli..
03/24 NOVO NORDISK A/S : Saxenda® approved in Europe for the treatment of obesity
03/24 NOVO NORDISK A/S : -Saxenda approved in Europe for the treatment of obesity
03/24DJNOVO NORDISK A/S : Gets EU Marketing Approval for Obesity Treatment
More news
Sector news : Pharmaceuticals - NEC
09:54p CELGENE : MorphoSys And Celgene Agree To End MOR202 Collaboration
05:05pDJREGENERON PHARMACEUTICALS : Correction to Headline on Wednesday's Regeneron Stor..
04:02p AMGEN : Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® C..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:09p Portfolio Changes For The First Quarter Of 2015
01:38p Novo Nordisk trys again with Tresiba and Ryzodeg NDA resubmission to FDA
07:56a Novo's faster-acting insulin matches NovoRapid
03/24 Bristol-Myers Squibb nabs exclusive license for autoimmune diseases discovery..
03/23 Novo Nordisk's obesity med cleared in Europe


Comments 
Advertisement
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO.B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF